Turrill M, Spicer D V, Kelley A S, Herman R L, Russell C A, Muggia F M
Department of Medicine, University of Southern California, Los Angeles.
Cancer Invest. 1995;13(2):160-4. doi: 10.3109/07357909509011685.
Twenty-five women with advanced breast carcinoma refractory to first-line chemotherapy entered a phase II trial to evaluate the efficacy of ifosfamide and carboplatin. Additionally the trial assessed the clinical usefulness of oral 2-mercaptoethane sulfonate (mesna) for urothelial protection. Two partial remissions were observed (8%); toxicity was significant but acceptable, with no treatment-related deaths. The combination of ifosfamide and carboplatin had little activity as the second-line treatment in our population of patients with heavily pretreated metastatic breast cancer. Oral mesna was effective for urothelial protection, permitting outpatient administration of ifosfamide.
25例一线化疗难治的晚期乳腺癌女性患者进入一项II期试验，以评估异环磷酰胺和卡铂的疗效。此外，该试验还评估了口服2-巯基乙烷磺酸盐（美司钠）对尿路保护的临床实用性。观察到2例部分缓解（8%）；毒性显著但可接受，无治疗相关死亡。在我们这群经过大量预处理的转移性乳腺癌患者中，异环磷酰胺和卡铂联合作为二线治疗几乎没有活性。口服美司钠对尿路有保护作用，允许门诊使用异环磷酰胺。
